Zila divertiture approved
This article was originally published in The Tan Sheet
Executive Summary
Zila receives shareholder approval to divest wholly-owned subsidiary Zila Nutraceuticals to NBTY, the Phoenix-based firm announces Sept. 28. The company expects the divestiture to be completed Oct. 2 for $37.5 mil. in a total cash transaction with up to an additional $3 mil. to be paid through an "earn-out formula dependent upon the future performance of the business." NBTY in August announced the proposed acquisition of the nutraceutical division, which includes the Ester-C and Ester-E branded ingredients (1"The Tan Sheet," Aug. 21, 2006, p. 5)...
You may also be interested in...
NBTY Expands Into Mass Market With Zila Acquisition
NBTY is looking to use Ester-C brand recognition and loyalty to gain traction in the mass retail market
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.